Wed.Dec 06, 2023

article thumbnail

Discovery Park Ventures expands fund to £3m to invest in more innovative science and technology start-ups

Drug Discovery Today

DPV has plans to further expand the fund up to £25m in the next three years with a focus on companies developing novel and disruptive technologies that have strong collaborative relationships with Discovery Park.

Science 113
article thumbnail

New protein linked to early-onset dementia identified

Science Daily: Pharmacology News

Scientists have identified abnormal aggregates of a protein called TAF15 in the brains of individuals with early-onset dementia, known as frontotemporal dementia, where the cause was not previously known.

124
124
article thumbnail

BugBiome wins Discovery Spark life science programme

Drug Discovery Today

• BugBiome wins a business support package worth over £100,000, including one year of free lab space at Discovery Park and £50,000 investment from Discovery Park Ventures• BioMavericks awarded the wildcard prize as voted for by the audience at the GIANT Health Healthcare Investment Show on 5th December

Science 113
article thumbnail

AbbVie to buy Cerevel in $8.7B bet on brain drugs

BioPharma Drive: Drug Pricing

The deal hands AbbVie a portfolio of psychiatric medicines that originated within Pfizer, among them a closely watched schizophrenia treatment that’s in late-stage testing.

Treatment 124
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

let?7g sensitized liver cancer cells to 5?fluorouracil by downregulating ABCC10 expression

Chemical Biology and Drug Design

let-7g sensitized the response of liver cancer cells to 5-FU by targeting ABCC10, prolonging the G1 phase and promoting apoptosis. These findings provide new insights into the chemotherapy resistance of HCC. Abstract Patients with advanced liver cancer may benefit from 5-fluorouracil (5-FU) therapy. However, most of them eventually faced drug resistance, resulting in a poor prognosis.

article thumbnail

Neuroprotectant Activity of Novel Water-Soluble Synthetic Neurosteroids on Organophosphate Intoxication and Status Epilepticus-induced Long-term Neurological Dysfunction, Neurodegeneration and Neuroinflammation [Neuropharmacology]

ASPET

Organophosphates (OP) and nerve agents are potent neurotoxic compounds that cause seizures, status epilepticus, brain injury or death. There are persistent long-term neurological and neurodegenerative effects that manifest months to years after the initial exposure. Current antidotes are ineffective in preventing these long-term neurobehavioral and neuropathological changes.

Therapies 100

More Trending

article thumbnail

Bowtie resonators that build themselves bridge the gap between nanoscopic and macroscopic

Science Daily: Pharmacology News

Two nanotechnology approaches converge by employing a new generation of fabrication technology. It combines the scalability of semiconductor technology with the atomic dimensions enabled by self-assembly.

113
113
article thumbnail

Spotting Epilepsy in Kids Isn't Always Easy: Know the Signs

Drugs.com

WEDNESDAY, Dec. 6, 2023 -- Neurologist Dr. Deborah Holder says she often has parents come to her with kids who've experienced what they call "funny spells." “Sometimes I start talking to a parent and find out the parent has [also] had.

105
105
article thumbnail

New protein linked to early-onset dementia identified

Drug Discovery Today

Researchers have established a first potential therapeutic target for a type of early-onset dementia.

Research 113
article thumbnail

Novartis gets FDA approval of closely watched rare disease drug

BioPharma Drive: Drug Pricing

The pharma is developing Fabhalta, now cleared for paroxysmal nocturnal hemoglobinuria, for several other rare, complement-driven diseases.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Folks at High Risk of Heart Disease May Gain From Eating Mackerel, Tuna

Drugs.com

WEDNESDAY, Dec. 6, 2023 -- Folks with a family history of heart disease might benefit from eating more oily fish like salmon, mackerel, herring and sardines, a new study finds.Oily fish contain high levels of omega-3 fatty acids, which cannot be.

Disease 98
article thumbnail

Researchers redesign future mRNA therapeutics to prevent potentially harmful immune responses

SCIENMAG: Medicine & Health

Researchers have discovered that misreading of therapeutic mRNAs by the cell’s decoding machinery can cause an unintended immune response in the body. They have identified the sequence within the mRNA that causes this to occur and found a way to prevent ‘off-target’ immune responses to enable the safer design of future mRNA therapeutics.

article thumbnail

Folks at High Risk of Heart Disease May Gain From Eating Mackerel, Salmon

Drugs.com

WEDNESDAY, Dec. 6, 2023 -- Folks with a family history of heart disease might benefit from eating more oily fish like salmon, mackerel, herring and sardines, a new study finds. Oily fish contain high levels of omega-3 fatty acids, which cannot be.

Disease 98
article thumbnail

Fascicle gearing dynamics: Unveiling 3D rotation effects in muscle elongation

SCIENMAG: Medicine & Health

Detailed insights into muscle and tendon movement mechanisms during stretching are essential to improve our overall mobility and flexibility. It is not only important for optimum athletic performance, but also crucial for preventing musculoskeletal injuries. When an individual stretches, 50% to 70% of the elongation is absorbed into the muscle belly, i.e.

85
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Starting Periods Early Linked to Higher Odds for Diabetes, Stroke

Drugs.com

WEDNESDAY, Dec. 6, 2023 -- Girls whose periods begin before the age of 13 are at higher risk of becoming adult women with diabetes, compared to girls who start menstruation later, new research shows.An earlier onset of periods also appears to hike.

article thumbnail

First map of human limb development reveals unexpected growth processes and explains syndromes found at birth

SCIENMAG: Medicine & Health

Human fingers and toes do not grow outward; instead, they form from within a larger foundational bud, as intervening cells recede to reveal the digits beneath. This is among many processes captured for the first time as scientists unveil a spatial cell atlas of the entire developing human limb, resolved in space and time.

84
article thumbnail

Minorities Expect and Prepare for Unfair Health Care, Survey Shows

Drugs.com

WEDNESDAY, Dec. 6, 2023 -- Few people look forward to doctor visits, but a new survey shows that many minorities feel a deep sense of dread. Some even try to dress especially well for their visit, to try and ward off the possibility they'll face.

Doctors 98
article thumbnail

New SureChEMBL announcement

The ChEMBL-og

(Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents!

article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

New Weight-Loss Drug Zepbound Is Now Available, Company Says

Drugs.com

WEDNESDAY, Dec. 6, 2023 -- The newly approved weight-loss medication known as Zepbound is now available for patients to take, drug maker Eli Lilly announced Tuesday. "Today opens another chapter for adults living with obesity who have been looking.

Drugs 85
article thumbnail

The Year in AdComms – A Look Back at 2023

Eye on FDA

For those working closely with the development of new medicines for FDA approval, it can be informative respecting the future to look back at recent activity and take note of any potential changes from years past. Now, with no more AdComms scheduled for 2023 – and it being highly unlikely that any will be – it is that time of year to do just that.

FDA 77
article thumbnail

Biotech venture firms continue ‘recalibration’ in third quarter, Pitchbook report finds

BioPharma Drive: Drug Pricing

Data collected by the research firm suggests venture funding totals are still sliding amid a "strategic shift" by investors towards fewer, but more substantial deals.

article thumbnail

Jays jump in while crows hold out for the treat

Science Daily: Pharmacology News

New research has found that two similar species of birds behave very differently around their favorite food when they have company. Biologists compared the behavior of two species of corvids, Eurasian jays and New Caledonian crows, both capable of displaying self-control through delayed gratification. The researchers found that jays will settle for an immediate, less preferred food option when another bird is present, while crows will always hold out for their favorite food, regardless of the so

article thumbnail

Covalent targeting of non-cysteine residues in PI4KIII?

Covalent Modifiers

Brett Cosgrove, Emma K. Grant, Sophie Bertrand, Kenneth D. Down, Don O. Somers, John P. Evans d, Nicholas C. O. Tomkinson and Michael D. Barker RSC Chem. Biol. , 2023, 4, 1111-1122 DOI: 10.1039/D3CB00142C The synthesis and characterisation of fluorosulfate covalent inhibitors of the lipid kinase PI4KIIIβ is described. The conserved lysine residue located within the ATP binding site was targeted, and optimised compounds based upon reversible inhibitors with good activity and physicochemical profi

Drugs 74
article thumbnail

First map of human limb development reveals unexpected growth processes and explains syndromes found at birth

Science Daily: Pharmacology News

Scientists reveal unprecedented insights into human limb development, including the many intricate processes that govern their formation.

article thumbnail

Covalent PROTAC design method based on a sulfonyl pyridone probe

Covalent Modifiers

Qinhong Luo, Yaqi Wang, Zhanfeng Hou, Huiting Liang, Licheng Tu, Yun Xing, Chuan Wan, Jianbo Liu, Rui Wang, Lizhi Zhu, Wei Han, Jianlong Wu, Fei Lu, Feng Yin and Zigang Li Chem. Commun. , 2024 DOI: 10.1039/D3CC05127G Covalent proteolysis-targeting chimeras (PROTACs) offer enhanced selectivity, prolonged action, and increased efficacy against challenging target proteins.

article thumbnail

NIH awards $9 million for Indigenous-led Tribal Data Repository to improve community health in response to COVID-19 pandemic

SCIENMAG: Medicine & Health

In an effort to improve the health of Tribal communities and Indigenous people, the National Institutes of Health (NIH) has awarded $9 million in funding for Native scientists at Arizona State University and elsewhere to create the first Indigenous-led Tribal Data Repository.

72
article thumbnail

Beyond the lab: cancer research

Drug Target Review

Dear readers, Welcome to this report on cancer research, where we explore the latest breakthroughs in cancer research. In three comprehensive chapters, we explore recent developments that promise to reshape the landscape of cancer treatment. Expert insights Patrick Kendall, Artelo Biosciences through his consulting company, KendallPharma ltd Dr Benjamin Neuditschko, Postdoc at IMC University of Applied Sciences Krems’ Institute Krems Bioanalytics Dr Andy Souers, Research Fellow on the Oncology

article thumbnail

New patent for Zealand Pharma drug ZEGALOGUE

Drug Patent Watch

Annual Drug Patent Expirations for ZEGALOGUE Zegalogue is a drug marketed by Zealand Pharma and is included in one NDA. It is available from two suppliers. There is one patent… The post New patent for Zealand Pharma drug ZEGALOGUE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 64
article thumbnail

Drug Manufacturer Auditing: Ensuring Quality, Control, and Safety

Cytel

Chemistry, Manufacturing, and Controls (CMC) is a critical component of drug product development. As a Senior Consultant in Drug Development, I serve as a representative for sponsors with the Contract Development and Manufacturing Organization (CDMO). The CDMO manufactures drug substances or drug formulations for safety studies and investigational drugs for clinical trials.

article thumbnail

What CVS Pharmacy’s New Cost-Plus Reimbursement Approach Means for PBMs, Pharmacies, Plan Sponsors, and Prescription Prices

Drug Channels

Is the world ready for new ways to price pharmacy and pharmacy benefit manager (PBM) services? CVS Health thinks so, as evidenced by two new initiatives that it announced yesterday. Below you'll find details and links to source documents. I commend CVS Health for attempting to address key economic challenges facing the retail pharmacy industry and for tackling the hidden complexities of PBM pricing models.

article thumbnail

Light therapy may improve symptoms of Alzheimer’s disease

SCIENMAG: Medicine & Health

Light therapy leads to significant improvements in sleep and psycho-behavioral symptoms for patients with Alzheimer’s disease, according to a new study published this week in the open-access journal PLOS ONE by Qinghui Meng of Weifang Medical University, China, and colleagues.

article thumbnail

Fujifilm to invest $200M in cell therapy production

BioPharma Drive: Drug Pricing

The funds are meant to boost Fujifilm’s capacity to manufacture cell therapies, a market it expects to grow substantially in the coming years.

article thumbnail

Beyond the lab: screening

Drug Target Review

Dear readers, Today’s drug screening methods predominantly rely on one or two types of data, limiting their ability to replicate the intricate nature of disease biology. However, the advent of advanced screening techniques capable of processing numerous data sources simultaneously has unearthed novel hits that have eluded us throughout the history of medicine.